Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What you think? .005-.007 this may drop to. I've been watching this since September and it hasn't hit subs yet.
Check out the monthly operating report filed on 10-31-18 on PRIME Clerk. Stock holder equity of 177.5 million and positive cash flow of 7.4 million. with number like that, hopefully we will see other bidders in the auction.
A stalking horse offer, agreement, or bid is an attempt by a bankrupt debtor to test the market for the debtor's assets in advance of an auction of them.[1][2] The intent is to maximize the value of its assets or avoid low bids, as part of (or before) a court auction.[3]
Please explain what a stalking horse bid is?
Liabilities in the hundred million dollar range? Liquidation planned, shareholders receive $0... Let me know if the scenario changes... TIA
Something's happening. Usually, with these Q stocks, i need a 2-day volume confirmation. Let's see what happens today.
Yep. When a Q stock that has a net worth of 23.5mil is generating unusual volume a week after a stalking horse bid of 4xs its net worth gets submitted...I start listening!!
Thinking we might be looking at the next Q-runner...ala BIOAQ and BONTQ. missed the latter even though I saw the volume. Still made about that one!!
ARLZQ
23.5mil in assets here. Stalking Horse's bid is quadruple that. Hmmmm.....
I wonder if anyone realizes that there is a near $100mil Stalking Horse offer on the table for ARLZQ. Not sure if it includes anything for the commons. I need to check if Nuvo is public or private. I believe private.
Hard to miss the unusual volume here though. Another I've been eyeballing for a minute.
It's doing great today, I see...
As said, it's all for trading. It'll take a while for its settlement. So, trading for making.
Great - Good luck with the liquidation stock...
ARLZ, 52 week high: $2.98. Those who bought at dollars won't give up so easily for losing so big money. They're trying their best to cover their huge losses. Sooner, it'll skyrocket once they get enough cheap shares!
It's all for trading: those who bought at high pps like you are averaging down and will push it higer to make money.
LIQUIDATION - means it's done bud... I already posted that when it was about .05... I will use the loss against my other gains this year... GLTY
You averaged down at $0.30's? Now, it's only $0.02, you should Average down more, bud!
Wow! ARLZ, from $2.98 to $0.02 ! What a Run!
ARLZ changed to ARLZQ. Delisted from the Nasdaq to the OTC:
http://otce.finra.org/DLAdditions
Heads up for those who don't know. I didn't. I use fidelity to purchase stocks. When it came to penny stocks I could not buy more than 4,999 shares at at time; thus incurring a $4.95 fee for every batch I bought. I'm mentioning this because I see a number of orders that are the same I.e 100 at a time. If you call your brokerage firm and ask to be coded for penny stocks, your upper limits will be removed and you can save on those multiple fees they charge.
I apologize for those who knew this already.
Yea, I was WRONG about the bounce, but since everything else I have thought about this POS company was wrong, I'm not surprised, lol...
Anyway, they have filed to LIQUIDATE... Usually the common shareholders get $0 in a bankruptcy liquidation, so be very very careful here folks...
* * $ARLZ Video Chart 08-13-18 * *
Link to Video - click here to watch the technical chart video
* * $ARLZ Video Chart 08-10-18 * *
Link to Video - click here to watch the technical chart video
Put it into QTMM and at least recover your losses in the near future.
Yes, and with LIQUIDATION... no need to hope for any bounce either, imo...
Just sell out and liquidate and Cancel all shares.... sheesh...
you called it Doc.....
ec
I warned of this BANKRUPTCY on July 6th- link back... took my losses and at least got something back...
Who said Nasdaq's are safe? LOL
CLAY only knows how to draw horizontal lines. Then say it might go up, might go down.
another broken company where CLAY has uploaded videos previously ... chance?
lol going to 000000 its BK and selling assets
everyone is selling going to .01
ec
$250M agreement?
* * $ARLZ Video Chart 08-09-18 * *
Link to Video - click here to watch the technical chart video
* * $ARLZ Video Chart 07-23-18 * *
Link to Video - click here to watch the technical chart video
Bid / Ask in Premarket is looking good.
Dead cat bounce or some fundamental reason for the reversal?
* * $ARLZ Video Chart 07-20-18 * *
Link to Video - click here to watch the technical chart video
With you on this one this is dying reverse splits in the future
I'd wait for an earnings report... they may bankrupt at this rate...
i have been watching arlz since may
will probably jump in when it hits mid teens
ec
I hear you ADXS was the thorn in my investments glty
Yea, I sold after the annual meeting when there wasn't even a glimmer of a rally. Biggest loss of the year for me... Oh well, I have a lot of gains to offset, lol, but I don't like to lose big...
Yeah and it looks like ADXS is on that path.Very sad
Looks like they are guiding to bankruptcy? Sheesh...
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
470
|
Created
|
02/05/16
|
Type
|
Free
|
Moderators |
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. It also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women?s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company is headquartered in Milton, Canada.
Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 2, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 9.
151 Steeles Avenue East
Milton, ON L9T 1Y1
Canada
905-876-1118
http://www.aralez.com
Sector:
Industry:
Full Time Employees:
Name | Title | Pay | Exercised | Age |
---|---|---|---|---|
Mr. Adrian Adams | Chief Exec. Officer and Director | 1.02M | N/A | 66 |
Mr. Andrew I. Koven | Pres and Chief Bus. Officer | 683.18k | N/A | 59 |
Mr. Scott J. Charles | Chief Financial Officer | 653.07k | N/A | 42 |
Mr. Mark A. Glickman | Chief Commercial Officer | 504.94k | N/A | 51 |
Mr. John E. Barnhardt CPA | Principal Accounting Officer and VP of Fin. & Admin. | N/A | N/A | 67 |
SHARE THIS ARTICLE
-First Quarter 2017 Net Revenues of $26.0 Million-
-Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance-
-Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month-
MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.
"We are pleased to report a solid first quarter of 2017, together with important updates to our business addressing a number of the challenges we face," said Adrian Adams, Chief Executive Officer of Aralez. "We are making a bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year. We also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative M&A with the goal of enhancing shareholder value."
Company Highlights:
"Deerfield Partners remains fully supportive of Aralez and its management team as the company navigates its way through recent challenges," said James Flynn, Managing Partner at Deerfield. "We are encouraged by the new pricing strategy for Yosprala and the prospects for Zontivity."
Cost Savings Initiatives
The Company previously announced in April 2017 that it had begun implementing cost savings initiatives as part of the Company's ongoing objective to maximize value from its assets and preserve financial flexibility. The total expected operating expense reduction in 2017 of approximately $23.0 million includes the previously announced 32% reduction in its U.S. sales force, which is expected to yield 2017 savings of approximately $5.5 million ($7.5 million on an annual basis), a decrease of approximately $9.0 million in 2017 commercial spend, which primarily relates to non-direct marketing spend on Yosprala, and decreased 2017 departmental expenses across the business of approximately $8.5 million. While Aralez has made significant reductions to its expenses, the Company plans to invest an additional $7.0 million to support a successful phased launch of Zontivity that commenced on April 24, 2017, which the Company views as an increasingly attractive opportunity. The Company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value.
First Quarter 2017 Financial Results
Aralez's financial results for the three months ended March 31, 2016 include the operations of Tribute Pharmaceuticals Canada Inc. (Tribute) from February 5, 2016, the closing date of the Pozen and Tribute merger transaction (the Merger), through March 31, 2016, but do not include the results of Zontivity or Toprol-XL and its currently marketed authorized generic (the Toprol-XL franchise) as these acquisitions were completed on September 6, 2016 and October 31, 2016, respectively. Aralez's financial results for the three months ended March 31, 2017 include the results of Tribute, Zontivity and the Toprol-XL franchise.
Total revenues for the three months ended March 31, 2017 were $26.0 million compared to $8.1 million for the three months ended March 31, 2016. Net product revenues of $6.7 million for the three months ended March 31, 2017 primarily related to the product portfolio acquired with the acquisition of Tribute as well as net product revenues from Yosprala and Fibricor®. Other revenues of $19.3 million for the three months ended March 31, 2017 were comprised of net revenues of $15.6 million from the acquisitions of the Toprol-XL franchise and Zontivity, which are recorded net of related cost of product revenues and fees paid during the respective transition service periods, and Vimovo® royalties of $3.7 million. Pursuant to the Company's agreement with Horizon in the U.S., subject to certain conditions described in our public filings, Aralez is guaranteed a quarterly minimum royalty amount (calculated based on a minimum annual royalty of $7.5 million), which was reflected in the Company's first quarter results. Net product revenues of $3.6 million for the three months ended March 31, 2016 related to the Tribute product portfolio acquired in the Merger, which was completed on February 5, 2016. Other revenues of $4.5 million for the three months ended March 31, 2016 were comprised solely of Vimovo royalties.
Cost of product revenues were $2.8 million for the three months ended March 31, 2017 compared to $2.5 million for the three months ended March 31, 2016. The increase related primarily to costs of product revenues for the full quarter in 2017 from the Company's product portfolio that was acquired as part of the Merger in February 2016.
SG&A expenses were $30.8 million for the three months ended March 31, 2017 compared to $37.5 million for the three months ended March 31, 2016. The decrease in SG&A expenses was primarily driven by costs related to the Merger in the prior year of approximately $19.4 million, partially offset by increased costs related to the build out of our U.S. sales force in 2016 and increased promotional expenses in the U.S. during the first quarter of 2017.
R&D expenses for the three months ended March 31, 2017 were $0.1 million compared to $4.4 million for the three months ended March 31, 2016. The decrease related primarily to higher costs incurred in the first quarter of 2016 for Yosprala in advance of its U.S. approval in September 2016.
Amortization of intangible assets of $8.5 million for the three months ended March 31, 2017 related to the acquisitions of Tribute, Zontivity and the Toprol-XL franchise. Amortization of intangible assets for the three months ended March 31, 2016 of $1.3 million related solely to the acquisition of Tribute.
The change in fair value of contingent consideration of $4.4 million for the three months ended March 31, 2017 related to accretion for the Toprol-XL franchise and Zontivity acquisitions. There was no expense related to fair value changes in contingent consideration for the three months ended March 31, 2016.
Interest expense of $6.7 million for the three months ended March 31, 2017 was primarily attributable to the borrowing of $200 million under the Company's credit facility in the fourth quarter of 2016 in connection with the acquisitions of Zontivity and the Toprol-XL franchise and $75 million convertible notes. Interest expense of $0.3 million for the three months ended March 31, 2016 related to the $75 million convertible notes.
Other income, net for the three months ended March 31, 2017, was $0.4 million compared to $4.8 million for the three months ended March 31, 2016, a decrease of $4.4 million. The decrease principally related to a $4.6 million decrease in the fair value of the warrants liability acquired from Tribute during the prior year, offset by a $0.3 million gain from the sale of a building in London, Ontario during the three months ended March 31, 2017.
The net loss for the three months ended March 31, 2017 was $27.5 million, or $0.42 loss per share on a fully diluted basis, compared to a net loss for the three months ended March 31, 2016 of $33.8 million, or $0.73 loss per share on a fully diluted basis.
Adjusted EBITDA was ($3.6) million for the three months ended March 31, 2017 compared to Adjusted EBITDA of ($11.1) million for the three months ended March 31, 2016.
Balance Sheet
As of March 31, 2017, approximately 65.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $73.7 million.
Updated 2017 Guidance
Aralez's estimates are based on projected results of the Company for the year ending December 31, 2017 and reflect management's current beliefs and expectations about, among other things, prescription trends, competition, pricing levels, inventory levels, and anticipated future events. The Company's guidance on Adjusted EBITDA includes, among other things, costs to support the commercialization efforts with respect to Yosprala, Zontivity and the Canadian product portfolio as well as costs to support the global corporate structure. It excludes share-based compensation expense and certain discrete costs, including merger and product acquisition-related expenses. See "Use of Non-GAAP Financial Measures" below.
For the year ending December 31, 2017, assuming, among other factors more particularly set out in "Cautionary Note Regarding Forward-Looking Statements" below, the Company currently expects:
See the table below for a comparison of the Company's original 2017 guidance compared to the updated 2017 guidance:
Measure | 2017 Original Guidance | 2017 Updated Guidance |
Net Revenues | $80 million to $100 million | $80 million to $100 million |
Adjusted EBITDA | $(25) million to $(10) million | $(5) million to $5 million |
First Quarter Results Webcast
Aralez will host a webcast this morning, May 9, 2017 at 9:00 a.m. ET to present results for the first quarter 2017. The webcast can be accessed live and will be available for replay at www.aralez.com.
Conference Call Details
Date: Tuesday, May 9, 2017
Time: 9:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |